Live Feed

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --    -- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS -- -- Company to hold conference call on Saturday, June 13, at 8 a.m. CT, 9 a.m. ET -- BOSTON, June 13, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced preliminary data from a Phase 2 trial

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Cl

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and is the first Phase 3 study of a GPRC5D bispecific investigational combinationResults reinforce Johnson & Johnson's leadership in multiple myeloma, advancing bispecific combinations earlier in the treatment journey, and expanding options to match the right treatment to the right patient and stage of diseaseSTOCKHOLM, June 13, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announc

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy's has collaborated with MSN Laboratories Private Limited ("MSN"), a leading pharmaceutical company in India, on this product. Dr. Reddy's holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product. Bosutini

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed across prespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global re

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferr

4 - PROCORE TECHNOLOGIES, INC. (0001611052) (Issuer)

4 - IonQ, Inc. (0001824920) (Issuer)

4 - IonQ, Inc. (0001824920) (Issuer)

4 - IonQ, Inc. (0001824920) (Issuer)

4 - GARMIN LTD (0001121788) (Issuer)

4 - IonQ, Inc. (0001824920) (Issuer)

4 - Acushnet Holdings Corp. (0001672013) (Issuer)

4 - United Parks & Resorts Inc. (0001564902) (Issuer)

4 - United Parks & Resorts Inc. (0001564902) (Issuer)

4 - United Parks & Resorts Inc. (0001564902) (Issuer)

4 - KULR Technology Group, Inc. (0001662684) (Issuer)

3 - KULR Technology Group, Inc. (0001662684) (Issuer)

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53

Crews focus on remaining outages as weather clears across northern Illinois ComEd crews continue restoring power to customers impacted by multiple rounds of severe storms that moved through northern Illinois beginning Wednesday afternoon. With the most volatile weather now past the region, crews are focused on completing repairs and restoring service to remaining pockets of customers affected by storm damage. Multiple bands of severe weather brought intense rain, frequent lightning and high wind gusts, causing significant damage to ComEd's power infrastructure and resulting in widespread outages across the service territory. At least two tornadoes were confirmed on Thursday, including o